Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
San Mateo, Santa Rosa, East Bay, Modesto, Palo Alto/Santa Cruz, Greater Sacramento
Valley, San Francisco, Solano/Vallejo
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab